Perrigo Announces Quarterly Dividend
Perrigo Company plc (NYSE: PRGO) announced a quarterly dividend of $0.26 per share, payable on December 20, 2022, to shareholders of record on December 2, 2022. This decision reflects the company's ongoing commitment to shareholder value as a leading provider of Consumer Self-Care Products. The press release also discusses forward-looking statements related to their investments in infant formula capacity and highlights potential risks including the impact of COVID-19, economic conditions, and ongoing litigation.
- Quarterly dividend of $0.26 per share demonstrates commitment to shareholder value.
- Dividend payment indicates confidence in financial stability.
- Potential risks associated with COVID-19 and supply chain disruptions.
- Ongoing legal disputes that may affect financial performance.
DUBLIN, Nov. 3, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of
Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com.
Forward-Looking Statements
Certain statements in this press release, including statements regarding expected costs and benefits of investments in infant formula capacity, are "forward-looking statements." These statements relate to future events or the Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "forecast," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the effect of the coronavirus (COVID-19) pandemic and its variants and associated supply chain impacts on the Company's business; general economic, credit, and market conditions; the impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business; the risk that potential costs or liabilities incurred or retained in connection with the Company's sale of its Rx business may exceed the Company's estimates; and resolution of uncertain tax positions, including the Company's appeal of the draft and final Notices of Proposed Assessment ("NOPAs") issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceedings would have on operating results, cash flows, and liquidity; pending and potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NOPAs. An adverse result with respect to the Company's appeal of any material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2021, and Form 10-Q for the quarter ended July 2, 2022, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-announces-quarterly-dividend-301667981.html
SOURCE Perrigo Company plc
FAQ
What is the amount of Perrigo's quarterly dividend for December 2022?
When will Perrigo's dividend be paid?
What is the record date for Perrigo's December dividend?
What factors could impact Perrigo's future financial performance?
